Currency In USD
| Previous Close | 11.1 |
| Open | 11.13 |
| Day High | 11.13 |
| Day Low | 11.13 |
| 52-Week High | 11.41 |
| 52-Week Low | 2.87 |
| Volume | 10.31M |
| Average Volume | 5.72M |
| Market Cap | 994.04M |
| PE | -5.27 |
| EPS | -2.11 |
| Moving Average 50 Days | 8.21 |
| Moving Average 200 Days | 6.45 |
| Change | 0.03 |
Data not available
Verve Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following i
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewswire Inc.
Apr 14, 2025 11:00 AM GMT
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related ser
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewswire Inc.
Apr 11, 2025 11:00 AM GMT
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track